We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis.
- Authors
Yang, Jin; Tian, Qing; Tang, Yuexin; Shah, Arvind K.; Zhang, Ruya; Chen, Guojuan; Zhang, Ye; Rajpathak, Swapnil; Hong, Tianpei
- Abstract
Introduction: To evaluate the efficacy and safety of dipeptidyl peptidase 4 inhibitors (DPP4i) used in combination with insulin in patients with type 2 diabetes mellitus (T2DM). Methods: We searched the MEDLINE, Embase, and Cochrane library databases for randomized controlled trials (RCTs) published through June 2018. Studies with at least a 12-week treatment period were included to compare the addition of DPP4i to insulin with insulin control therapy. Meanwhile, groups on a stable insulin dosage (insulin-stable subgroup) or titrating insulin dosage (insulin-flexible subgroup) were analyzed separately. Results: Twenty-one RCTs with 3697 patients randomized to a DPP4i/insulin treatment arm and 3538 to an insulin control arm were included. DPP4i, when added to insulin therapy, led to a significantly greater reduction in HbA1c (− 0.57%, 95% CI − 0.66, − 0.48) and provided significantly greater odds of achieving the HbA1c target < 7% (OR 3.45; 95% CI 2.58, 4.63). These effects were achieved in the context of a decrease in the daily insulin requirement, without increases in hypoglycemia risk and body weight, compared with the control treatment. Subgroup analysis showed control-adjusted reductions in HbA1c from baseline in the insulin-stable subgroup (− 0.64%; 95% CI − 0.74, − 0.53) and the insulin-flexible subgroup (− 0.43%; 95% CI − 0.56, − 0.30). Other results occurred similarly in both subgroups. Conclusions: The addition of DPP4i to insulin is associated with a statistically significant reduction in glycemic control as measured by HbA1c, fasting plasma glucose, and 2-h postprandial glucose, without increasing the risk of hypoglycemia and weight gain. These conclusions were also observed in both stable-dose and flexible-dose insulin subgroups.
- Subjects
CD26 antigen; SODIUM-glucose cotransporters; TYPE 2 diabetes; CANAGLIFLOZIN; BLOOD sugar; INSULIN; META-analysis
- Publication
Diabetes Therapy, 2020, Vol 11, Issue 10, p2371
- ISSN
1869-6953
- Publication type
Article
- DOI
10.1007/s13300-020-00914-x